I-BET151 (GSK1210151A), BET Inhibitor


Catalog No. size PriceQuantity
M66053-2D 10 mM in DMSO (0.482 mL) $109
M66053-2S 2mg solid $109
M66053-10S 10 mg solid $447

Description

I-BET151 (GSK1210151A) is a novel and selective inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2, BRD3, and BRD4 with IC50 of ~0.5 μM, 0.25 μM, and 0.79 μM respectively. It has profound effects on human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis. The mode of action of I-BET151 is, at least in part, due to the inhibition of transcription at key genes (BCL2, C-MYC and CDK6) through the displacement of BRD3/4, PAFc and SEC components from chromatin. In vivo studies indicate that I-BET151 can provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia. I-BET151 is also an ApoA1 upregulator that was also found to mediate potent anti-inflammatory effects. It showed a broad anti-inflammatory profile in a LPS-challenged Balb/C mouse model.

Product information

CAS Number: 1300031-49-5

Molecular Weight: 415.44

Formula: C23H21N5O3

Synonym:

GSK1210151A

Chemical Name: 7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one

Smiles: COC1=CC2=C3C(=CN=C2C=C1C1C(C)=NOC=1C)NC(=O)N3[C@H](C)C1=CC=CC=N1

InChiKey: VUVUVNZRUGEAHB-CYBMUJFWSA-N

InChi: InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 100mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

I-BET151 was used at 10 µM final concentration in various in vitro assays.

In Vivo:

IP administration of I-BET151 at 30 mg/kg once per day was shown to provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia. Oral administration of I-BET151 at 10 mg/kg once per day in mice showed efficacy in acute inflammation mouse model.

References:

  1. Dawson MA, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. (2011) Nature. 478(7370):529-33.
  2. Mirguet O, et al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. (2012) Bioorg Med Chem Lett. 22(8):2963-7.
  3. Seal J, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). (2012) Bioorg Med Chem Lett. 22(8):2968-72.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed